Receptors for luteinizing hormone-releasing hormone (LHRH) in benign prostatic hyperplasia (BPH) as potential molecular targets for therapy with LHRH antagonist cetrorelix

Prostate

Volumn 71, Issue 5, 2011, Pages 445-452

  Rozsa, Bernadett ^a   Nadji, Mehrdad ^b   Schally, Andrew V ^b,c   Dezso, Balazs ^d   Flasko, Tibor ^d   Toth, Gyorgy ^d   Mile, Melinda ^a   Block, Norman L ^b   Halmos, Gabor ^a,b,c  

^a UNIVERSITY OF DEBRECEN   (Hungary)

^b UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

^d UNIVERSITY OF DEBRECEN   (Hungary)

Author keywords

human benign prostatic hyperplasia; LHRH antagonist; luteinizing hormone releasing hormone (LHRH) receptors

Indexed keywords

CETRORELIX; GONADORELIN; GONADORELIN RECEPTOR; MEMBRANE PROTEIN; MESSENGER RNA;

ADULT; AGED; ARTICLE; BINDING AFFINITY; DRUG BINDING SITE; DRUG RECEPTOR BINDING; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTATE HYPERTROPHY; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; RADIOASSAY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TRANSURETHRAL RESECTION;

AGED; AGED, 80 AND OVER; BINDING, COMPETITIVE; GONADOTROPIN-RELEASING HORMONE; HORMONE ANTAGONISTS; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; MOLECULAR TARGETED THERAPY; PROSTATIC HYPERPLASIA; RADIOLIGAND ASSAY; RECEPTORS, LHRH; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER;

EID: 79951521997     PISSN: 02704137     EISSN: 10970045     Source Type: Journal    
DOI: 10.1002/pros.21258     Document Type: Article

References (27)

1. Webber R,. Benign prostatic hyperplasia. Clin Evid 2006; 15: 1213-1226.
2. Lee KL, Peehl DM,. Molecular and cell (Pubitemid 39363056)
3. Lepor H,. Pathophysiology, epidemiology, and natural history of benign prostatic hyperplasia. Rev Urol 2004; 6: 3-10.
4. Oesterling JE,. Benign prostatic hyperplasia: A review of its histogenesis and natural history. Prostate Suppl 1996; 6: 67-73. (Pubitemid 26112291)
5. Isaacs JT,. Importance of the natural history of benign prostatic hyperplasia in the evaluation of pharmacologic intervention. Prostate Suppl 1990; 3: 1-7. (Pubitemid 20127947)
6. De Bellis A, Ghiandi P, Comerci A, Fiorelli G, Grappone C, Milani S, Salerno R, Marra F, Serio M,. Epidermal growth factor, epidermal growth factor receptor, and transforming growth factor-alpha in human hyperplastic prostate tissue: Expression and cellular localization. Journal Clin Endocrinol Metab 1996; 81: 4148-4154. (Pubitemid 26380431)
7. Ropiquet F, Giri D, Lamb DJ, Ittmann M,. FGF7 and FGF2 are increased in benign prostatic hyperplasia and are associated with increased proliferation. J Urol 1999; 162: 595-599. (Pubitemid 29434402)
8. Culig Z, Hobisch A, Cronauer MV, Radmayr C, Hittmair A, Zhang J, Thurnher M, Bartsch G, Klocker H,. Regulation of prostatic growth and function by peptide growth factors. Prostate 1996; 28: 392-405. (Pubitemid 26187724)
9. Tammela T,. Benign prostatic hyperplasia. Practical treatment guidelines. Drugs Aging 1997; 10: 349-366. (Pubitemid 27202086)
10. Lepor H,. The role of gonadotropin-releasing hormone antagonists for the treatment of benign prostatic hyperplasia. Rev Urol 2006; 8: 183-189.
11. Engel JB, Schally AV,. Drug insight: Clinical use of agonists and antagonists of luteinizing-hormone-releasing hormone. Nat Clin Pract Endocrinol Metab 2007; 3: 157-167. (Pubitemid 46146968)
12. Debruyne F, Gres AA, Arustamov DL,. Placebo-controlled dose-ranging phase 2 study of subcutaneously administered LHRH antagonist cetrorelix in patients with symptomatic benign prostatic hyperplasia. Eur Urol 2008; 54: 170-180.
13. Bajusz S, Csernus V, Janaky T, Bokser L, Fekete M, Schally AV,. New antagonists of LH-RH: II. Inhibition and potentiation of LH-RH by closely related analogues. Int J Pept Protein Res 1988; 32: 425-435. (Pubitemid 19042048)
14. Reissmann TH, Engel J, Kutscher B, Bernd M, Hilgard P, Peukert M, Szelenyi I, Reichert S, Gonzalez-Barcena D, Nieschlag E,. Cetrorelix. Drugs Future 1994; 19: 228-237. (Pubitemid 24137365)
15. Schally AV, Halmos G, Rekasi Z, Arencibia JM,. GnRH analogs. In:, Devroey P, editor. Infertility and Reproductive Medicine Clinics of North America. Philadelphia: Saunders; 2001; 120: 11-19.
16. Gonzalez-Barcena D, Vadillo-Buenfil M, Gomez-Orta F, Fuentes Garcia M, Cardenas-Cornejo I, Graef Sanchez A, Comaru-Schally AM, Schally AV,. Responses to the antagonistic analog of LH-RH (SB-75, Cetrorelix) in patients with benign prostatic hyperplasia and prostatic cancer. Prostate 1994; 24: 84-92. (Pubitemid 24073107)
17. Comaru-Schally AM, Brannan W, Schally AV, Colcolough M, Monga M,. Efficacy and safety of luteinizing hormone-releasing hormone antagonist Cetrorelix in the treatment of symptomatic benign prostatic hyperplasia. J Clin Endocrinol Metab 1998; 83: 3826-3831. (Pubitemid 28513557)
18. Siejka A, Schally AV, Block NL, Barabutis N,. Mechanism of action of inhibition of human benign prostatic hyperplasia in vitro by LHRH antagonist cetrorelix. Br J Urol Int 2010; Feb 11. [Epub ahead of print]
19. Halmos G, Arencibia JM, Schally AV, Davis R, Bostwick DG,. High incidence of receptors for luteinizing hormone-releasing hormone (LHRH) and LHRH receptor gene expression in human prostate cancers. J Urol 2000; 163: 623-629. (Pubitemid 30060537)
20. Munson PJ, Rodbard DA,. A versatile computerized approach for characterization of ligand binding systems. Anal Biochem 1980; 107: 220-239.
21. Scatchard B,. The attraction of proteins for small molecules and ions. Ann NY Acad Sci 1949; 51: 660-672.
22. Peters CA, Walsh PC,. The effect of nafarelin acetate, a luteinizing hormone-releasing hormone agonist, on benign prostatic hyperplasia. N Engl J Med 1987; 317: 599-604. (Pubitemid 17118986)
23. Gabrilove JL, Levine AC, Kirschenbaum A, Droller M,. Effect of long-acting gonadotropin-releasing hormone analog (leuprolide) therapy on prostatic size and symptoms in 15 men with benign prostatic hypertrophy. J Clin Endocrinol Metab 1989; 69: 629-632. (Pubitemid 19221238)
24. Horvath J, Toller G, Schally AV, Bajo A-M, Groot K,. Effect of long-term treatment with low doses of the LHRH antagonist Cetrorelix on pituitary receptors for LHRH and gonadal axis in male and fenale rats. Proc Natl Acad Sci U S A 2004; 101: 4996-5001. (Pubitemid 38469191)
25. De Reijke TM, Burk K, Kurth K,. Clinical and endocrinological results of patients treated with the LHRH antagonist (cetrorelix). Eur Urol 1996; 30: 57 (Abstract no.245).
26. Lepor H, Dixon C, Crawford ED, Steidle C, Oesterling J,. A randomized double blind placebo controlled phase II study of the safety and efficacy of cetrorelix in men with BPH. J Urol 1997; 157: 146 (abstract no.531).
27. Debruyne F, Tzvetkov M, Altarac S, Geavlete PA,. Dose-ranging study of the LH-RH receptor antagonist cetrorelix pamoate in the treatment of patients with symptomatic benign prostatic hyperplasia. Urology 2010; (accepted, in print).